Sökning: WFRF:(Rosendahl Jonas)
> Ahlgren Johan >
The risk of amenorr...
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients : Data from the randomised SBG 2000-1 study
-
Rosendahl, Mikkel (författare)
-
Ahlgren, Johan (författare)
-
Andersen, Jorn (författare)
-
visa fler...
-
- Bergh, Jonas (författare)
- Karolinska Institutet
-
- Blomquist, Carl (författare)
- Uppsala universitet,Enheten för onkologi
-
Lidbrink, Elisabet (författare)
-
- Lindman, Henrik (författare)
- Uppsala universitet,Enheten för onkologi
-
Mouridsen, Henning (författare)
-
Bjerre, Karsten (författare)
-
Andersson, Michael (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2009
- 2009
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 45:18, s. 3198-3204
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Study aim: Amenorrhoea is a common side-effect to chemotherapy of premenopausal women. We examine the association between chemotherapy-induced leucopaenia and the development of amenorrhoea in premenopausal women with breast cancer. Materials and methods: in a multi-centre, randomised, controlled study, 1016 premenopausal women received seven series of FEC (F: fluorouracil, E: epirubicin and C: Cyclophosphamide) for early stage breast cancer. In the first series, all patients received standard dose (F: 600 mg/m(2), E: 60 mg/m(2) and C: 600 mg/m(2)). Patients with leukocyte nadir 1.0-1.9 x 10(9)/l continued with standard dose for the remaining six series (STANDARD(REGISTERED), n = 279). Patients with leukocyte nadir >= 2 x 10(9)/l were randomised to standard (STANDARD(RANDOMISED), n = 373) or increased (TAILORED, n = 364) dose of E and C. After each series, leukocyte nadir was evaluated. Absent bleeding after the 5th-7th series of FEC was interpreted as amenorrhoea. Results: The risk of amenorrhoea increased with age. In age-stratified analysis of the STANDARD groups (equal dose, different initial leukocyte nadir) low leukocyte nadir was associated with amenorrhoea for patients in the age-group 25-39 years (P = 0.010). In age-stratified analysis in the randomised groups (different doses, same initial leukocyte nadir) a dose related increased risk of amenorrhoea was found for age-groups 25-39 (RR: 1.15, 95% confidence interval (CI): 1.06-1.24) and 40 44 years (RR:1.21, 95% CI: 1.001-1.47). Conclusion: Age is the most important risk factor of amenorrhoea after FEC chemotherapy. However, for younger patients, lower leukocyte nadir in response to STANDARD FEC treatment or increased doses of C and E were associated with increased risk of amenorrhoea. (C) 2009 Elsevier Ltd. All rights reserved.
Nyckelord
- Breast cancer
- Amenorrhoea
- Ovarian failure
- Menopause
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rosendahl, Mikke ...
-
Ahlgren, Johan
-
Andersen, Jorn
-
Bergh, Jonas
-
Blomquist, Carl
-
Lidbrink, Elisab ...
-
visa fler...
-
Lindman, Henrik
-
Mouridsen, Henni ...
-
Bjerre, Karsten
-
Andersson, Micha ...
-
visa färre...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet